Log in

Relevant bibliographies by topics / He52 / Journal articles

To see the other types of publications on this topic, follow the link: He52.

Journal articles on the topic 'He52'

Author: Grafiati

Published: 28 July 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'He52.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Yagisawa, Masataka, Kentaro Sawada, Yoshiaki Nakamura, et al. "Molecular landscape and prognostic value of HER2 low-expression on metastatic colorectal cancer." Journal of Clinical Oncology 38, no. 4_suppl (2020): 229. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.229.

Full text

Abstract:

229 Background: HER2 dual blockade showed the promise in clinical trials in patients (pts) with HER2-positive (HER2-Pos) metastatic colorectal cancer (mCRC). A phase I/II study of a novel anti-HER2 antibody-drug conjugate (HER2-ADC) showed promising activities across different cancer subtypes including HER2-Pos mCRC, and also showed a hint of activity for low-expressing (HER2-L) mCRC, regardless of RAS mutation. However, molecular landscape and prognostic value of HER2-L on mCRC are unclear. Methods: The eligibility included pts with mCRC who had undergone surgical resection of primary tumor.

APA, Harvard, Vancouver, ISO, and other styles

2

Suchocki, Tomasz. "Performance and Emission Characteristics of a Small Gas Turbine Engine Using Hexanol as a Biomass-Derived Fuel." Materials 17, no. 23 (2024): 6011. https://doi.org/10.3390/ma17236011.

Full text

Abstract:

The global transition to renewable energy has amplified the need for sustainable aviation fuels. This study investigates hexanol, a biomass-derived alcohol, as an alternative fuel for small-scale gas turbines. Experimental trials were conducted on a JETPOL GTM-160 turbine, assessing blends of 25% (He25) and 50% (He50) hexanol with kerosene (JET A) under rotational velocities ranging from 40,000 to 110,000 RPM. The parameters measured included thrust-specific fuel consumption (TSFC), turbine inlet and outlet velocities, and the emission indices of NOx and CO. The results demonstrated that the H

APA, Harvard, Vancouver, ISO, and other styles

3

Hees, van, Martin. "Vrijheid en verantwoordelijkheid: nawoord." Algemeen Nederlands Tijdschrift voor Wijsbegeerte 105, no. 4 (2013): 257–64. http://dx.doi.org/10.5117/antw2013.4.hee2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hendriks, Petra, and Eric Reuland. "Waar komen de bindingscondities vandaan?" Nederlandse taalkunde 18, no. 2 (2013): 179–86. http://dx.doi.org/10.5117/nedtaa2013.2.hen2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

YENUGU, Suresh, Katherine G. HAMIL, Charles E. BIRSE, Steven M. RUBEN, Frank S. FRENCH, and Susan H. HALL. "Antibacterial properties of the sperm-binding proteins and peptides of human epididymis 2 (HE2) family; salt sensitivity, structural dependence and their interaction with outer and cytoplasmic membranes of Escherichia coli." Biochemical Journal 372, no. 2 (2003): 473–83. http://dx.doi.org/10.1042/bj20030225.

Full text

Abstract:

During passage through the epididymis, sperm interact with secreted epididymal proteins that promote maturation, including the acquisition of motility and fertilization competence. Viewed previously as distinct from sperm maturation, host defence capabilities are now recognized functions of the human epididymis 2 (HE2) family of sperm-binding proteins. We analysed the potent dose and time-dependent bactericidal activity of recombinant HE2α, HE2β1 and HE2β2 and found that the full-length proteins (10 μg/ml or ~1 μM) caused more than a 50% decrease in Escherichia coli colony forming units within

APA, Harvard, Vancouver, ISO, and other styles

6

Prat, A., O. Karginova, C. Fan, and C. M. Perou. "Notch-associated expression profiles in basal-like and claudin-low breast cancer molecular subtypes." Journal of Clinical Oncology 27, no. 15_suppl (2009): 11017. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.11017.

Full text

Abstract:

11017 Background: An attractive candidate target for breast cancer (BC) and BC tumor-initiating cells is the Notch signaling pathway. To better understand the potential dependence of breast cancer upon Notch-signaling, we used a genomic approach to study the activation of this pathway in the different molecular subtypes. Methods: Breast basal-like, luminal and HER2+ cell lines were examined for sensitivity to gamma-secretase inhibition (GSI). Gene expression data from the most sensitive cell line was analyzed during treatment and upon releasing from GSI (4h, 8h and 24h post-treatment). Using a

APA, Harvard, Vancouver, ISO, and other styles

7

Fang, Yutong, Qunchen Zhang, Yuan Wu, and Jundong Wu. "HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer." Medicine 103, no. 6 (2024): e37170. http://dx.doi.org/10.1097/md.0000000000037170.

Full text

Abstract:

The growing body of evidence suggests that breast cancer (BC) who achieve pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) may experience a more favorable prognosis. The objective of this study is to investigate the correlation between clinicopathologic parameters of locally advanced breast cancer (LABC) patients and the outcomes of NAC, with the aim of identifying predictive indicators for pCR. Additionally, we seek to examine the conversion of IHC markers in pCR patients following NAC and its impact on the prognosis of BC patients. We conducted a study involving 126

APA, Harvard, Vancouver, ISO, and other styles

8

Zhukova, L. G. Zhukova, E. V. Artamonova Artamonova, I. P. Ganshina Ganshina, et al. "Dual HER2 blockade with pertuzumab+trastuzumab on the eve of a new era in the treatment of HER2-positive breast cancer." Pharmateca 11_2021 (November 8, 2021): 57–65. http://dx.doi.org/10.18565/pharmateca.2021.11.57-65.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Craciun, Doina, Edwin A. Laszlo, Julia C. Mirza-Rosca, et al. "Structural Parameters and Behavior in Simulated Body Fluid of High Entropy Alloy Thin Films." Materials 17, no. 5 (2024): 1162. http://dx.doi.org/10.3390/ma17051162.

Full text

Abstract:

The structure, composition and corrosion properties of thin films synthesized using the Pulsed Laser Deposition (PLD) technique starting from a three high entropy alloy (HEA) AlCoCrFeNix produced by vacuum arc remelting (VAR) method were investigated. The depositions were performed at room temperature on Si and mirror-like polished Ti substrates either under residual vacuum (low 10−7 mbar, films denoted HEA2, HEA6, and HEA10, which were grown from targets with Ni concentration molar ratio, x, equal to 0.4, 1.2, and 2.0, respectively) or under N2 (10−4 mbar, films denoted HEN2, HEN6, and HEN10

APA, Harvard, Vancouver, ISO, and other styles

10

Liberko, Marián, and Renata Soumarová. "Her2 positive metastatic gastric cancer." Onkologie 18, no. 4 (2024): 249–53. http://dx.doi.org/10.36290/xon.2024.051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Liberko, Marián, and Renata Soumarová. "Her2 negative metastatic gastric cancer." Onkologie 18, no. 4 (2024): 244–48. http://dx.doi.org/10.36290/xon.2024.050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Légaré, Christine, Nancy Verville, and Robert Sullivan. "Vasectomy Influences Expression of HE1 but not HE2 and HE5 Genes in Human Epididymis." Journal of Andrology 25, no. 1 (2004): 30–43. http://dx.doi.org/10.1002/j.1939-4640.2004.tb02756.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Lee, In Hee, Byeongju Kang, Jeeyeon Lee, et al. "Abstract PO5-16-03: RT LAMP assay for the subtyping of breast cancer." Cancer Research 84, no. 9_Supplement (2024): PO5–16–03—PO5–16–03. http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-16-03.

Full text

Abstract:

Abstract Introduction Our previous study showed that direct reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay can be employed as a substitute in order to detect tumor involvement of lymph nodes within breast cancer patients. In this research, we aimed to investigate the potential applicability of RT-LAMP for the classification of breast cancer subtype. Method Breast Cancer Cell line RNA extraction Total RNA from the cell lines was isolated from cultured cells using RNAiso Plus (TaKaRa, Shiga, Japan) according to the manufacturer’s instructions; MCF10A, MCF7, T47D, BT

APA, Harvard, Vancouver, ISO, and other styles

14

Haber, O., I. Ben-Itzhak, I. Gertner, A. Mann, and B. Rosner. "Formation of He20and He22+molecules by charge exchange collisions of He2+ions in the sub-MeV region." Journal of Physics B: Atomic and Molecular Physics 18, no. 7 (1985): L201—L205. http://dx.doi.org/10.1088/0022-3700/18/7/007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Piccart, M. J., A. Di Leo, and A. Hamilton. "HER2." European Journal of Cancer 36, no. 14 (2000): 1755–61. http://dx.doi.org/10.1016/s0959-8049(00)00162-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Barcenas, Carlos Hernando, Kenneth R. Hess, Yann Delpech, et al. "Survival outcomes in HER2-positive invasive lobular breast carcinoma." Journal of Clinical Oncology 30, no. 15_suppl (2012): 612. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.612.

Full text

Abstract:

612 Background: HER2-positive (HER2+) invasive lobular breast carcinoma (ILC) is a rare entity and survival outcomes are not well characterized. Methods: We retrospectively searched for breast cancer patients treated at MD Anderson Cancer Center between 1992 and 2010 with a diagnosis of early stage (I-III) HER2+ILC or with HER2+ invasive mixed ductal/lobular carcinoma (MIX). With the purpose of comparing survival outcomes, we looked for patients with a diagnosis of HER2-negative [HER2(-)] ILC, HER2(-)MIX, and HER2+ invasive ductal carcinomas (IDC). We obtained data on demographics, estrogen (E

APA, Harvard, Vancouver, ISO, and other styles

17

Wong, Rachel Su Jen, Jingming Chew, Eunice Teo, Zhong Wee Poh, Joline SJ Lim, and Shaheenah S. Dawood. "Transcriptomic analysis of HER2 expression in metastatic breast cancer: Insights from a UAE patient cohort." Journal of Clinical Oncology 43, no. 16_suppl (2025): 1024. https://doi.org/10.1200/jco.2025.43.16_suppl.1024.

Full text

Abstract:

1024 Background: HER2-low metastatic breast cancer (mBC) has emerged as a clinically significant subgroup since approval of trastuzumab deruxtecan. However, its relevance as a distinct subtype remains debated. We aimed to identify HER2-related gene signatures, examine the molecular characteristics of HER2-low mBC, and investigate the potential for classifying HER2-low mBC into subgroups with profiles resembling either HER2-positive (HER2+) or HER2-negative (HER2-) mBC. Methods: We performed differential gene expression (DGE) analysis using the TCGA-BRCA dataset, comparing HER2+ and HER2- sampl

APA, Harvard, Vancouver, ISO, and other styles

18

Omar, Abeid Mohamed Athman, and Azza Mohamad Amin Darwish. "Retrospective analysis of HER2-low in young breast cancer patients." Journal of Clinical Oncology 39, no. 15_suppl (2021): e12515-e12515. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e12515.

Full text

Abstract:

e12515 Background: Traditionally, breast cancer (BC) is considered human epidermal growth factor receptor-2 (HER2) positive based on HER2 overexpression or amplification (HER2 3+ or ISH positive HER2 2+). However, an emerging subgroup of HER2 negative (HER2 1+ or 2+ and ISH negative) known as HER2-Low is associated with poor prognosis than HER2-normal (HER2 0). Currently, there is an increased interest in developing new drugs targeting HER2-Low BC to improve survival. The fact that BC in young constitutes a significant minority outside the western world but is underrepresented in clinical tria

APA, Harvard, Vancouver, ISO, and other styles

19

White, Colin D., Zhigang Li, and David B. Sacks. "Calmodulin binds HER2 and modulates HER2 signaling." Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1813, no. 5 (2011): 1074–82. http://dx.doi.org/10.1016/j.bbamcr.2010.12.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

von Kieseritzky, Kathrin. "HER2-Blockade beim HER2-positiven frühen Mammakarzinom." Im Focus Onkologie 21, no. 10 (2018): 25. http://dx.doi.org/10.1007/s15015-018-4218-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

red. "Doppelte HER2-Blockade beim HER2-positivem Mammakarzinom." Im Focus Onkologie 21, no. 12 (2018): 78. http://dx.doi.org/10.1007/s15015-018-4386-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Ignatov, Tanja, Franceska Gorbunow, Holm Eggemann, Olaf Ortmann, and Atanas Ignatov. "Loss of HER2 after HER2-targeted treatment." Breast Cancer Research and Treatment 175, no. 2 (2019): 401–8. http://dx.doi.org/10.1007/s10549-019-05173-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Zagozdzon, Radoslaw, William M. Gallagher, and John Crown. "Truncated HER2: implications for HER2-targeted therapeutics." Drug Discovery Today 16, no. 17-18 (2011): 810–16. http://dx.doi.org/10.1016/j.drudis.2011.06.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Ahn, Sung Gwe, Yoonwon Kook, Soong June Bae, Sae Byul Lee, and Joon Jeong. "Comparisons between HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 ER+ HER2- breast cancer." JCO Global Oncology 9, Supplement_1 (2023): 13. http://dx.doi.org/10.1200/go.2023.9.supplement_1.13.

Full text

Abstract:

13 Background: HER2-positivity is an essential marker for therapeutic decisions, while HER2 expression is heterogenous. In recent years, there has been increasing recognition of a subgroup of breast cancer patients who have low levels of HER2 expression, also known as HER2-low because trastuzumab deruxtecan offers clinical benefit for patients with HER2-low metastatic breast cancer. Despite the growing interest in HER2-low breast cancer, there is limited research on how multigene assays can help differentiate between HER2-low and HER2-negative breast cancer. Among ER+HER2- breast cancer, we co

APA, Harvard, Vancouver, ISO, and other styles

25

Major, Molly, Christine S. Nervig, Annette Gerland, and Shawn C. Owen. "Surface-Available HER2 Levels Alone Are Not Indicative of Cell Response to HER2-Targeted Antibody–Drug Conjugate Therapies." Pharmaceutics 16, no. 6 (2024): 752. http://dx.doi.org/10.3390/pharmaceutics16060752.

Full text

Abstract:

HER2-targeting therapies have advanced breast cancer treatment over the past decade. Clinically, eligibility for HER2 therapies is determined by assessing HER2 levels on tumor cell surfaces through immunohistochemistry or by gene regulation through fluorescence in situ hybridization. HER2 therapies are not always effective in patients with elevated levels of HER2, questioning whether the amount of HER2 is sufficiently predictive of patient outcomes. Additionally, the HER2-targeting antibody–drug conjugate (ADC) Enhertu® was recently approved for metastasized HER2-low cancers, confirming the be

APA, Harvard, Vancouver, ISO, and other styles

26

Wang, Biyun, Shuhui You, and Yannan Zhao. "Clinicopathological characteristics, evolution, treatment patterns and outcomes of hormone-receptor-positive/HER2-low-positive metastatic breast cancer: A retrospective analysis." Journal of Clinical Oncology 41, no. 16_suppl (2023): e13058-e13058. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e13058.

Full text

Abstract:

e13058 Background: HER2-low positivity is more prevalent in breast cancers with positive hormone receptor (HR). Patients with HR-positive and low HER2 expression may have different prognosis and characteristics. Nevertheless, research focusing on HR-positive/HER2-low-positive breast cancer remains scarce. Methods: This study included 458 patients with HR-positive/HER2-negative metastatic breast cancer (HR+/HER2- MBC) who received first- or second-line endocrine therapy at the Fudan University Shanghai Cancer Center (FUSCC) between July 2010 and October 2022. Results: Clinicopathological charac

APA, Harvard, Vancouver, ISO, and other styles

27

Akay, Seval, Mumin Emiroglu, Canan Kelten Talu, and Olcun Umit Unal. "Comparison of Clinicopathological Characteristics for HER2-Null, HER2-Ultralow and HER2-Low Breast Cancer: A Single-Center Study." Medicina 61, no. 4 (2025): 719. https://doi.org/10.3390/medicina61040719.

Full text

Abstract:

Background and Objectives: A recent clinical trial has demonstrated that breast cancer with low-HER2 expression levels responds to trastuzumab deruxtecan treatment. This has prompted a re-evaluation of HER2-targeted therapies in the HER2-negative group. Further research is required in the form of more detailed information about HER2-negative breast cancers with HER2-null, HER2-ultralow, and HER2-low subgroups. This study represents a novel approach to this field. Materials and Methods: HER2-negative breast cancer patients were classified into three groups as HER2-null, HER2-ultralow, and HER2-

APA, Harvard, Vancouver, ISO, and other styles

28

Pospíšková, Markéta, and Milan Kohoutek. "Breast cancer a chronic disease? The Anti-HER2 therapy." Klinická farmakologie a farmacie 30, no. 4 (2016): 28–30. http://dx.doi.org/10.36290/far.2016.032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Liberko, Marián, and Renata Soumarová. "Current treatment options of HER2+ metastatic colorectal carcinoma." Onkologie 18, no. 3 (2024): 208–12. http://dx.doi.org/10.36290/xon.2024.039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Manguso, Nicholas, Jeffrey Johnson, Reva Kakkar Basho, Heather L. McArthur, Hisashi Tanaka, and Armando E. Giuliano. "Impact of neoadjuvant HER2-directed therapy on HER2 status in breast cancer." Journal of Clinical Oncology 35, no. 15_suppl (2017): e12130-e12130. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e12130.

Full text

Abstract:

e12130 Background: Neoadjuvant chemotherapy (NAC) with HER2-directed therapy has become standard-of-care for most women with potentially curable HER2-positive (HER2+) breast cancer and is associated with a high pathologic complete response (pCR) rate. The HER2 status of residual disease after NAC is not well characterized and could potentially inform clinical decisions about additional systemic therapy. We describe tumoral HER2 status before and after NAC with HER2-directed therapy. Methods: An institutional database was screened to identify patients with stage 1-3 HER2+ breast cancer by fluor

APA, Harvard, Vancouver, ISO, and other styles

31

Polidorio, Natália, Srinivasa Sevilimedu Veeravalli, Giacomo Montagna, Tiana Le, and Monica Morrow. "Do HER2 low tumors have a distinct clinicopathologic phenotype?" Journal of Clinical Oncology 41, no. 16_suppl (2023): 570. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.570.

Full text

Abstract:

570 Background: Clinicopathologic features of breast cancer subtypes defined by hormone receptor (HR) and HER2 status differ. These analyses classified HER2 IHC <3+ with negative FISH as HER2-. With the recognition of the clinical relevance of HER2 low, there is debate as to whether this is a distinct subtype. We sought to determine if features of HER2 low tumors differ from HER2- and HER2+ after controlling for HR status. Methods: Patients undergoing upfront surgery from 1998 to 2010 were identified from a prospectively maintained institutional database. HER2 status was classified by IHC/F

APA, Harvard, Vancouver, ISO, and other styles

32

Ardor, Gokce Deniz, Miglena K. Komforti, Helena Hanna, Onur Ibanoglu, Abigail Lochala, and Aziza Nassar. "Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients." Breast Journal 2023 (August 25, 2023): 1–7. http://dx.doi.org/10.1155/2023/9725647.

Full text

Abstract:

Introduction. Recent trials demonstrated clinically significant benefits in HER2-nonamplified breast cancer with HER2-low expression using novel anti-HER2 antibody-drug conjugates. Thus, HER2-low breast cancer was proposed as a separate diagnostic entity. Herein, we reclassify HER2-negative cancers according to the new HER2-low category using a modified system and further investigate HER2-very-low expression. Methods. 114 HER2 immunohistochemistry (IHC)-negative invasive breast tumors were identified from the pathology database of Mayo Clinic, Jacksonville, FL, between January 2019 and August

APA, Harvard, Vancouver, ISO, and other styles

33

Pereslete, Alyssa, Melissa Hughes, Alyssa Patterson, et al. "Abstract PS11-06: Analysis of HER2 expression changes from breast primary to brain metastases including HER2 Low and impact on overall survival." Cancer Research 84, no. 9_Supplement (2024): PS11–06—PS11–06. http://dx.doi.org/10.1158/1538-7445.sabcs23-ps11-06.

Full text

Abstract:

Abstract Background: Previous studies have shown that breast cancer receptor subtype switching between matched primary and metastatic brain metastases (BrM) is common. HER2 expression at low levels, termed “HER2 Low”, has emerged as a new therapeutic biomarker for highly active antibody drug conjugates with potential intracranial activity. Trastuzumab deruxtecan is FDA approved for the treatment of HER2 Low and HER2 positive breast cancer with emerging evidence of CNS responses and clinical benefit in patients with BrM. This study aimed to investigate the relationship between HER2 expression i

APA, Harvard, Vancouver, ISO, and other styles

34

Fernandez-Morales, L. A., E. Dalmau, S. Martinez, et al. "Analysis of the pathological response to primary chemotherapy in patients with locally advanced breast cancer (LABC) grouped according to ER, PR and HER2 status." Journal of Clinical Oncology 24, no. 18_suppl (2006): 626. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.626.

Full text

Abstract:

626 Background: The determination of ER and PR has a considerable importance when evaluating the prognosis and the response to treatment in breast cancer (BC). Assessment of HER2 status is also a standard for the management of BC. Hormone receptors (HR), HER2, and increasingly, genomic profiles distinguish at least four major classes of BC: HER2+; HER2-HR+, which can be divided into two classes, favorable and unfavorable; and basal-like that express neither HER2 nor HR. In the clinical practice is possible to divided BC according to ER, PR and HER2: ER-PR-HER2+, ER-PR-HER2-, ER+PR+HER2-, ER+RP

APA, Harvard, Vancouver, ISO, and other styles

35

Hensing, Whitney L., Shana N. Thomas, Sherif El-Refai, Elizabeth Mauer, Cynthia Ma, and Ron Bose. "Abstract P2-23-10: Gene expression and mutation profiles in HER2-mutated metastatic breast cancer." Cancer Research 83, no. 5_Supplement (2023): P2–23–10—P2–23–10. http://dx.doi.org/10.1158/1538-7445.sabcs22-p2-23-10.

Full text

Abstract:

Abstract Background: HER2 activating mutations occur in 2-5% of metastatic breast cancer (MBC) patients. These mutations cluster in the kinase domains and at amino acids 309-310 in the extracellular domain. The MutHER, SUMMIT, and PlasmaMATCH clinical trials have shown neratinib monotherapy or neratinib plus fulvestrant combination produce clinical benefit in 28% to 46% in HER2-mutated MBC patients, but median progression-free survival was only 3.6 to 5.4 months. In order to improve the knowledge and outcomes for patients with HER2-mutated MBC, we compared the mutational landscape and gene exp

APA, Harvard, Vancouver, ISO, and other styles

36

Matić, Ivana Z., Milica Grujić, Branka Kolundžija, et al. "White blood cell subsets in HER2-positive breast cancer patients treated with trastuzumab in relation to clinical outcome." Pathol Res Pract 224 (July 4, 2021): 153543. https://doi.org/10.1016/j.prp.2021.153543.

Full text

Abstract:

To examine whether HER2+ breast cancer patients who have decreased immune effector cells could respond well to trastuzumab, we evaluated the alterations in circulating immune system cell subsets: CD16+ and/or CD56+ lymphocytes, lymphocytes and granulocytes in these patients before and after treatment with trastuzumab-based regimens in relation to clinical response to therapy. The study involved 55 patients with HER2+ breast cancer before and 2 months after the initiation of the therapy. Progressive disease was confirmed in nine out of 55 patients (non-responders), while other patients achieved

APA, Harvard, Vancouver, ISO, and other styles

37

Viale, Giuseppe, Naoki Niikura, Eriko Tokunaga, et al. "Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics." Journal of Clinical Oncology 40, no. 16_suppl (2022): 1087. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1087.

Full text

Abstract:

1087 Background: Approximately 50% of BCs traditionally categorized as HER2 negative (HER2-neg) express low levels of HER2 (IHC 1+ or IHC 2+/ISH-; Miglietta, NPJ Breast Cancer 2021). HER2-targeted therapies for HER2-low metastatic BC (mBC) are under investigation (eg, T-DXd in the phase 3 DESTINY-Breast04 study; NCT03734029), but HER2 assays currently used to select patients (pts) for approved anti-HER2 therapies are optimized for high HER2 expression and are not validated for HER2-low detection. A recent study found relatively poor agreement (<70% interrater agreement) in evaluation of IHC

APA, Harvard, Vancouver, ISO, and other styles

38

Silvestri, Valentina, Virginia Valentini, Agostino Bucalo, et al. "HER2-Low Expression in Male Breast Cancer: Results from a Multicenter Series in Italy." Cancers 16, no. 3 (2024): 548. http://dx.doi.org/10.3390/cancers16030548.

Full text

Abstract:

In the field of breast cancer care, a significant breakthrough has occurred with the recognition of HER2-low expression as a target for novel anti-HER2 antibody–drug conjugates (ADC). This discovery is reshaping the treatment landscape, challenging previous perceptions that considered HER2-low as clinically insignificant. The ability to target HER2-low expression is expected to have substantial clinical implications, irrespective of gender, including in cases of male breast cancer (MBC). However, an estimate of the prevalence of the HER2-low subtype in MBC is missing. This retrospective, obser

APA, Harvard, Vancouver, ISO, and other styles

39

Han, Song-Hee, Ki Hyun Ryu, and Ah-Young Kwon. "The Prognostic Impact of HER2 Genetic and Protein Expression in Pancreatic Carcinoma—HER2 Protein and Gene in Pancreatic Cancer." Diagnostics 11, no. 4 (2021): 653. http://dx.doi.org/10.3390/diagnostics11040653.

Full text

Abstract:

Pancreatic ductal adenocarcinoma (PDAC) is a lethal and clinically heterogeneous disease with a limited benefit from human epidermal growth factor receptor 2 (HER2)-targeted therapy. Recently, some studies have addressed the antitumoral effect of novel anti-HER2 drugs in HER2 low-expressing tumors. However, there have been few studies on the significance of low HER2 expression and genetic heterogeneity in PDAC. Using immunohistochemistry and dual-color silver-enhanced in situ hybridization based on the Trastuzumab for a gastric cancer scoring scheme, we evaluated HER2 protein expression, gene

APA, Harvard, Vancouver, ISO, and other styles

40

Tarantino, Paolo, Hersh V. Gupta, Melissa E. Hughes, et al. "Abstract HER2-05: HER2-05 Comprehensive genomic characterization of HER2-low breast cancer." Cancer Research 83, no. 5_Supplement (2023): HER2–05—HER2–05. http://dx.doi.org/10.1158/1538-7445.sabcs22-her2-05.

Full text

Abstract:

Abstract Background: About half of all breast cancers exhibit low HER2 expression. Despite lack of ERBB2 amplification, HER2-low tumors respond to trastuzumab deruxtecan (T-DXd), leading to the NCCN recommendation of T-DXd both for patients with HER2+ and HER2-low metastatic breast cancer (MBC). It remains however unclear if HER2-low represents a distinct molecular entity, as compared to HER2-0 MBC. Here, we compare the genomic landscape of HER2-low versus HER2-0 breast cancers in a large, single institution cohort. Methods: We identified consecutive patients with MBC seen at Dana-Farber Cance

APA, Harvard, Vancouver, ISO, and other styles

41

Petricoin, Emanuel F., Brian A. Corgiat, Joyce O’Shaughnessy, et al. "Abstract HER2-17: HER2-17 Novel Quantitative HER2 Assay for Determining Dynamic HER2 Expression in the HER2 IHC 0 “Ultra-Low” Setting: Implications for Precision Therapy in HER2- Breast Cancer." Cancer Research 83, no. 5_Supplement (2023): HER2–17—HER2–17. http://dx.doi.org/10.1158/1538-7445.sabcs22-her2-17.

Full text

Abstract:

Abstract Background: The HER2 antibody drug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (T-DXd) significantly improves outcomes over standard chemotherapy in pts with HER2-LOW (IHC 1+ and IHC 2+ FISH-) metastatic breast cancer (MBC). Data from the DAISY (NCT04132960) trial in pts with HER2 IHC 0 or “ultra low” MBC revealed median progression-free survival (PFS) of 4.2 mos vs 6.7 mos in HER2-LOW and 11.1 mos in HER2 3+ pts (Diéras V, et al. Cancer Res. 2022;82(4_Suppl):PD8-02). There is an urgent need to develop methods to accurately discern HER2 LOW expression versus HER2 IHC 0/ultra-low e

APA, Harvard, Vancouver, ISO, and other styles

42

Wu, Xian-Meng, Yong-Kang Qian, Hua-Ling Chen, Chen-Hua Hu, and Bing-Wei Chen. "Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis." Current Oncology 30, no. 9 (2023): 8444–63. http://dx.doi.org/10.3390/curroncol30090615.

Full text

Abstract:

Despite the development of HER2-targeted drugs, achieving favorable outcomes for patients with HR+/HER2+MBC remains challenging. This study utilized Bayesian Network Meta-analysis to compare the efficacy and safety of anti-HER2 combination regimens. The primary analysis focused on progression-free survival (PFS), while secondary analyses included objective response rate, overall survival (OS) and the incidence rate of grade 3/4 adverse events (AEs). A comprehensive search across seven databases identified 25 randomized controlled trials for inclusion in this meta-analysis. For patients eligibl

APA, Harvard, Vancouver, ISO, and other styles

43

Katayama, Ayaka, Islam M. Miligy, Sho Shiino, et al. "Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer." Modern Pathology 34, no. 7 (2021): 1271–81. http://dx.doi.org/10.1038/s41379-021-00738-5.

Full text

Abstract:

AbstractThe response of human epidermal growth factor receptor2 (HER2)- positive breast cancer (BC) patients to anti-HER2 targeted therapy is significant. However, the response is not uniform and a proportion of HER2-positive patients do not respond. This study aims to identify predictors of response in the neoadjuvant treatment and to assess the discordance rate of HER2 status between pre- and post-treatment specimens in HER2-positive BC patients. The study group comprised 500 BC patients treated with neoadjuvant chemotherapy (NACT) and/or neoadjuvant anti-HER2 therapy and surgery who had tum

APA, Harvard, Vancouver, ISO, and other styles

44

Lin, Mingxi, Ting Luo, Hui Zhang, Xichun Hu, Wentao Yang, and Jian Zhang. "HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort." Journal of Clinical Oncology 41, no. 16_suppl (2023): 1021. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1021.

Full text

Abstract:

1021 Background: Trastuzumab deruxtecan (T-DXd) was recently approved to treat unresectable/metastatic HER2-low breast cancer. However, patients whose primary tumor is HER2-0 but recurrent/metastatic lesion is HER2-low will lose therapeutic opportunities for T-DXd if a rebiopsy is not performed. In this study, with the largest sample size to date, we aimed to investigate the prevalence of HER2 status conversion. Moreover, it remains debated whether HER2-0 and HER2-low tumors have different prognoses, probably because previous studies did not assess HER2 status entirely based on recurrent/metas

APA, Harvard, Vancouver, ISO, and other styles

45

Iacuzzo, Cristiana. "HER2-Low Breast Cancer: Prognosis and Future Treatment Prospective." Journal of Cancer Research and Management 1, no. 1 (2022): 1–4. http://dx.doi.org/10.56391/jcrm.2022.1010.

Full text

Abstract:

The human epidermal growth factor 2 (HER2) is a tyrosine kinase belonging to the Human Epidermal Receptor family [1]. HER2 is amplified leading to HER2 overexpression in 15% of breast cancers (BC) [2]. HER2 overexpression leads to poor prognosis, but offers the unique possibility to use a targeted therapy with monoclonal antibodies. This therapeutic option has radically changed the history of HER2 BC [3]. HER2 overexpression represents at present the most powerful predictive factor for likeliness of response to anti-HER2 agents [5]. The HER2 status is routinely assessed either using immunohist

APA, Harvard, Vancouver, ISO, and other styles

46

Kobyakov, Dmitriy S., A. M. Avdalyan, A. F. Lazarev, E. L. Lushnikova, and L. M. Nepomnyaschikh. "Relationship between clinical and morphological parameters and survival in non-small cell lung cancer with protein expression and gene HER2-neu amplification." Russian Journal of Oncology 19, no. 5 (2014): 31–36. http://dx.doi.org/10.17816/onco40105.

Full text

Abstract:

Purpose. Study of the content ofprotein HER2 and gene HER2 , CEP17 in conjunction with clinical and morphological parameters and survival in non-small cell lung cancer. Material and methods. Investigated 218 surgery samples of non-small cell lung cancer. HER2 protein was determined by immunohistochemistry (clone 4B5, «Ventana») andgene HER2, CEP17 by hybridization in situ (SISH, «Ventana»). Results. Found relationship between the clinical and morphological parameters on the TNM system with protein HER2 status and CEP17 (for value N), protein HER2 status and gene HER2 amplification (for tumor h

APA, Harvard, Vancouver, ISO, and other styles

47

Viale, Giuseppe, Mark Basik, Naoki Niikura, et al. "Abstract HER2-15: HER2-15 Retrospective Study to Estimate the Prevalence and Describe the Clinicopathological Characteristics, Treatment Patterns, and Outcomes of HER2-Low Breast Cancer." Cancer Research 83, no. 5_Supplement (2023): HER2–15—HER2–15. http://dx.doi.org/10.1158/1538-7445.sabcs22-her2-15.

Full text

Abstract:

Abstract Background: About 60% of breast cancers (BCs) traditionally categorized as HER2 negative (HER2-neg; immunohistochemistry [IHC] 0, IHC 1+ or IHC 2+/in situ hybridization [ISH]–) express low levels of HER2 (HER2-low; IHC 1+ or IHC 2+/ISH–; Schettini, NPJ Breast Cancer 2021). In the phase 3 DESTINY-Breast04 trial (NCT03734029), trastuzumab deruxtecan (T-DXd) showed significantly longer progression-free survival and overall survival (OS) vs physician’s choice of chemotherapy in patients (pts) with HER2-low metastatic BC (mBC) who previously received chemotherapy (Modi, NEJM 2022). As HER2

APA, Harvard, Vancouver, ISO, and other styles

48

Ma, Lingjun, Lexin Wang, Xuan Li, et al. "Abstract P3-11-14: Differential response to neoadjuvant antiHER2 therapy between HER2 2+ISH+ and HER2 3+ in HER2-positive breast cancer: Is HER2 2+ISH+ a distinct subtype?" Clinical Cancer Research 31, no. 12_Supplement (2025): P3–11–14—P3–11–14. https://doi.org/10.1158/1557-3265.sabcs24-p3-11-14.

Full text

Abstract:

Abstract Background: Neoadjuvant chemotherapy with dual anti-HER2 therapy has become the standard neoadjuvant systematic treatment (NST) for HER2-positive breast cancer patients. However, the efficacy of neoadjuvant anti-HER2 therapy varies greatly, different HER2 protein expression level of tumor cell is one of the reasons. Several studies have shown that the HER2 protein expression level is an independent impact factor of pathologic complete response (pCR) rate, HER2 2+ISH+ group patients have a poorer response to NST. However, few studies have explored the relationship between the use of si

APA, Harvard, Vancouver, ISO, and other styles

49

Peiffer, Daniel S., Muriel Laine, Long Nguyen, et al. "Abstract 3099: Predicting response to trastuzumab deruxtecan in breast cancer using flow cytometry." Cancer Research 85, no. 8_Supplement_1 (2025): 3099. https://doi.org/10.1158/1538-7445.am2025-3099.

Full text

Abstract:

Background: Historically, characterization of HER2 status has focused on stratifying tumors that over express HER2, known as HER2-positive (HER2+) breast cancer (BC), and those that do not, known as HER2-negative (HER2-) BC. Approximately half of all BCs, considered HER2-, express low levels of HER2 by immunohistochemistry (IHC). Although HER2-low BCs are resistant to traditional HER2-targeted therapies, recent trials have demonstrated they are sensitive to the antibody drug conjugate (ADC) trastuzumab deruxtecan (T-DXd). Tumor expression of HER2 was hypothesized to be required for response to

APA, Harvard, Vancouver, ISO, and other styles

50

Nashed, Rebecca, Hannah Barger, Brooke Taylor Fishman, Dylan A. Schlyer, and Neeharika Srivastava Makani. "Clinicopathologic features of early stage HER2-low breast cancer." Journal of Clinical Oncology 41, no. 16_suppl (2023): e12545-e12545. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e12545.

Full text

Abstract:

e12545 Background: Breast cancer (BC) is the leading cause of cancer deaths in women worldwide. Traditionally, BC is divided into 3 categories: hormone receptor positive (HR+) if tumors overexpress either estrogen or progesterone receptors, HER2-positive (Pos) if tumors overexpress the human epidermal growth factor receptor protein (HER2), and triple negative if tumors lack overexpression of HER2, ER, or PR. 15% of all BC are HER2-Pos, which has poorer outcomes when compared to HER2-Neg. Early HER2 targeted therapies only showed benefit for treating tumors with high enough HER2 overexpression.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!